Search form

 

Press Releases


Axcan Pharma to present at C.E. Unterberg, Towbin Specialty Pharmaceutical Conference in New York


Oct 22, 2004 - 12:00 ET

MONT SAINT-HILAIRE, Quebec, Oct. 22 / - Axcan Pharma Inc.
("Axcan" or the "Company") today announced that on Thursday, October 28, 2004,
its President and Chief Executive Officer, Léon F. Gosselin, will present an
overview of the Company at the C.E. Unterberg, Towbin Specialty Pharmaceutical
Conference held in New York City. This presentation will take place at
1:00 P.M. ET.
    Interested parties can access the audio webcast of the presentation on
the Company's website at www.axcan.com .

    Axcan is a leading specialty pharmaceutical company involved in the field
of gastroenterology. The Company markets a broad line of prescription products
sold for the treatment of symptoms in a number of gastrointestinal diseases
and disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis.
Axcan's products are marketed by its own sales force in North America and
Europe. Its common shares are listed on the Toronto Stock Exchange under the
symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".

    "Safe Harbor" statement under the Private Securities Litigation Reform
    Act of 1995.
    ----------------------------------------------------------------------

    To the extent any statements made in this release contain information
    that is not historical, these statements are essentially forward looking
    and are subject to risks and uncertainties, including the difficulty of
    predicting FDA and other regulatory approvals, acceptance and demand for
    new pharmaceutical products, the impact of competitive products and
    pricing, new product development and launch, reliance on key strategic
    alliances, availability of raw materials, the regulatory environment,
    fluctuations in operating results and other risks detailed from time to
    time in the Company's filings with the Securities and Exchange Commission
    and the Canadian Multijurisdictional Disclosure System.


Julie M. Thibodeau, Manager, Investor 
Relations, Axcan Pharma Inc., (450) 467-5138 ext. 2062; www.axcan.com